Latest posts

  • On the passing of Tachi Yamada

    On the passing of Tachi Yamada

    Tadataka “Tachi” Yamada MD, KBE served as the Advisory Board Chair of our Institute since its founding almost ten years ago. His tremendous mentorship helped us in innumerable ways to grow from a single-PI Institute founded by David Baker to a group of five faculty and almost 200 scientists and…

  • RoseTTAFold: Accurate protein structure prediction accessible to all

    RoseTTAFold: Accurate protein structure prediction accessible to all

    Today we report the development and initial applications of RoseTTAFold, a software tool that uses deep learning to quickly and accurately predict protein structures based on limited information. Without the aid of such software, it can take years of laboratory work to determine the structure of just one protein. With RoseTTAFold,…

  • Annual Report 2021

    Annual Report 2021

    From our deep-learning research to our new clinical trials, we are pleased to present this overview of the progress made at the Institute for Protein Design during the past year. 2021 Annual Report

  • Dr. Roy awarded WRF translational funding

    Dr. Roy awarded WRF translational funding

    Washington Research Foundation (WRF) has awarded a $250,000 phase 2 technology commercialization grant to Anindya Roy, Ph.D., to further develop a novel miniprotein binder for the treatment of idiopathic pulmonary fibrosis (IPF). Roy, an acting instructor in David Baker’s lab at the University of Washington’s Institute for Protein Design (IPD),…

  • Two nanoparticle vaccines enter clinical trials

    Two nanoparticle vaccines enter clinical trials

    Two different candidate vaccines developed by researchers at the Institute for Protein Design recently entered human clinical trials. GBP510, a candidate COVID-19 vaccine, is undergoing a combined Phase 1/2 trial. Flu-Mos-v1, a candidate mosaic influenza vaccine, is undergoing Phase 1 testing. Candidate COVID-19 vaccine Our SARS-CoV-2 vaccine candidate was created…

  • Nanoparticle flu shot blocks seasonal and pandemic strains

    Nanoparticle flu shot blocks seasonal and pandemic strains

    IPD researchers together with collaborators at the National Institutes of Health have developed experimental flu shots that protect animals from a wide variety of seasonal and pandemic influenza strains. The lead vaccine candidate has entered human clinical testing at the NIH. If it proves safe and effective, these next-generation influenza…

  • George Ueda and James Lazarovits awarded WRF translational funding

    George Ueda and James Lazarovits awarded WRF translational funding

    The Washington Entrepreneurial Research Evaluation and Commercialization Hub (WE-REACH) has announced investments in three new awards, including one to researches at the Institute for Protein Design, to expedite early-stage product development for promising biomedical innovations. The three awards are intended to reduce skin injury from wound dressing, to treat COVID-19…

  • Companion proteins enhance antibody potency

    Companion proteins enhance antibody potency

    This week we report the design of new proteins that cluster antibodies into dense particles, rendering them more effective. In laboratory testing, such clustered antibodies neutralize COVID-19 pseudovirus, enhance cell signaling, and promote the growth of T cells more effectively than do free antibodies. This new method for enhancing antibody…

  • A deep learning approach to protein design

    A deep learning approach to protein design

    Scientists at the IPD and Ovchinnikov lab at Harvard have applied deep learning to the challenge of protein design, yielding a new way to quickly create protein sequences that fold up as desired. This breakthrough has broad implications for the development of protein-based medicines and vaccines. Computational protein design has…

  • trRosetta yields structures for every protein family

    trRosetta yields structures for every protein family

    The field of protein structure prediction has greatly advanced in recent years thanks to increasingly accurate deep-learning methods. A new such method, called trRosetta developed at the Institute for Protein Design, has now made thousands of protein structures available via EMBL-EBI’s Pfam and InterPro data resource. More than 6300 protein structures have been predicted…